NOVAVAX INC — Director's Dealing 2021

Feb 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NOVAVAX INC (NVAX)
CIK: 0001000694
Period of Report: 2020-02-18

Reporting Person: Glenn Gregory M (President, R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-18	Common Stock	S	80	$264.092	Disposed	5165	Direct
2021-02-18	Common Stock	S	361	$265.5246	Disposed	4804	Direct
2021-02-18	Common Stock	S	128	$266.6763	Disposed	4676	Direct
2021-02-18	Common Stock	S	268	$268.1904	Disposed	4408	Direct
2021-02-18	Common Stock	S	678	$269.2269	Disposed	3730	Direct
2021-02-18	Common Stock	S	319	$269.9346	Disposed	3411	Direct
2021-02-18	Common Stock	S	110	$271.1578	Disposed	3301	Direct
2021-02-18	Common Stock	S	205	$272.4283	Disposed	3096	Direct
2021-02-18	Common Stock	S	67	$273.6079	Disposed	3029	Direct
2021-02-18	Common Stock	S	48	$274.63	Disposed	2981	Direct
2021-02-18	Common Stock	S	32	$276.23	Disposed	2949	Direct
2021-02-18	Common Stock	S	65	$278.2705	Disposed	2884	Direct
2021-02-18	Common Stock	S	73	$279.2022	Disposed	2811	Direct

Footnotes

F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.90 to $264.22,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F3: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.08 to $266.02,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F4: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.44 to $266.96,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F5: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.63 to $268.59,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F6: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.69 to $269.68,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F7: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.75 to $270.24,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F8: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.82 to $271.61,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F9: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.90 to $272.77,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F10: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.54 to $273.67,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F11: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.91 to $278.62,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.

F12: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.00 to $279.41,
inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this
footnote.